SNOG SYMPOSIUM 2024 – Multidisciplinary Neuro-Oncology Meeting

460

SKU: 9818 Categories: ,

Description

 

SNOG SYMPOSIUM 2024

Multidisciplinary Neuro-Oncology Meeting

25th – 27th  April

Gothenburg
Sweden

Welcome to,

Scandinavian Society of Neuro-oncology (SNOG) symposium, which will be held at Clarion Hotel Draken, Olof Palmes Plats 2, Gothenburg, Sweden 25th – 27th April, 2024.

The symposium is targeted to clinical experts, clinical researchers, basic scientists and students who work with improving lives for patients with brain tumors.

Scandinavian Society of Neuro-oncology (SNOG) was established in 1980s with the overall aim to increase communication between Scandinavian neuro-oncology experts, including both basic scientists and clinicians. One important aim of SNOG is to facilitate new collaborations and improve those already established. The SNOG meeting is an excellent arena to exchange ideas, and this is the key event organized by the society.

Language: English
Number of Participants: 170
Form of Symposium: Lectures and discussion
Registration Fee: 4.600 SKR
Application deadline: March 25, 2024 – Note! Limited number  of places, first came – first served!

What is included in the registration fee?

Admission to all scientific sessions
Admission to exhibition
Final Program
Coffee/tea during breaks
Lunch April 25, April 26, April 27
Dinner April 26

 

Link to meeting registration:
https://cancerakademin.se/evenemang/snog-symposium-2024-multidisciplinary-neuro-oncology-meeting/

About hotel reservation
We highly recommend you to reserve a room at Clarion Hotel Draken, where the symposium is also held. They have reserved rooms for the participants with a special price.

More information about the hotel by this link https://www.strawberry.se/hotell/sverige/goteborg/clarion-hotel-draken/

You can reserve your hotel room by clicking the link below:
Clarion Hotel Draken 25-27 april 2024

Special prices for participants:
Room for one person (single room) 155 EUR per night
Room for two persons (double room) 175 EUR per night
All prices are per room and per night, including breakfast buffet, Wi-Fi and VAT.

These prices are valid until February 23, 2024.

NOTE! Hotel rooms are not included in the congress fee.  The hotel rooms have to be booked and paid by each participant.


ABSTRACT

The Scandinavian Neuro-oncology Group (SNOG) encourages the submission of abstracts concerning all categories of research involving tumors involving the central nervous system (clinical, pre-clinical, translational, qualitative, register-based, etc.) but also descriptions of completed or ongoing development or quality assurance projects within the field.

Submit your abstract to SNOG by e-mail to: monica.sandstrom@umu.se

The abstract submission deadline is Monday March 4, 2024.

Instructions

Language
Abstracts can be submitted in English.

Word limit
The character limit set for all abstract categories is 2 000 characters (excluding spaces). The character limit does not include the author names and affiliations or the references.

Structure
The abstract should include the following:

  • A title that reflect the content of the abstract
  • Names and affiliations of all authors, with the name of the presenting author either underlined or in bold
  • E-mail address of the presenting author
  • An introductory brief background indicating the rationale of the study
  • A brief description of methodological procedures
  • A summary of the results
  • A statement of the main conclusions
  • A brief reflection on clinical significance and future perspectives
  • References (if applicable)
  • Funding (if applicable)
  • Disclosures (if applicable)

 

Let us know if you primarily want:

  • Oral
  • Poster
  • No preference 

Poster presentation
Instructions for the making of posters will be sent to the presenting author in connection with a notification that the abstract has been accepted. During the meeting, a prize will be awarded to the presenter of the best poster!

 

We hope that this will be an interesting and productive meeting and look forward to see you in Gothenburg in April 2024.

Welcome!

Asgeir Jakola
Professor
President SNOG
on behalf of
SNOG Organizing committee

Members of the organising & scientific committee

Asgeir Jakola, Gothenburg, Sweden
Bjarne Winther Kristensen,  København, Denmark
Anja Smits, Gothenburg, Sweden
Maria Sandström, Umeå, Sweden
Jiri Bartek, Stockholm, Sweden
Roger Henriksson, Umeå, Sweden
Magnus Olivecrona, Örebro, Sweden
Helena Carén, Gothenburg, Sweden
Annelli Ozanne, Gothenburg, Sweden
Kirsi Rautajoki, Tampere, Finland.
Ole Solheim, Trondheim, Norway

Skriv ut
April 25        
12.00 - 12.10 Welcome Asgeir Jakola, Gothenburg/Sweden    
  Cognition - Chair - Anneli Ozanne      
12.10 - 12.40 Cognitive rehabilitation - lessons learned Karin Gehring, Tillburg/The Netherlands    
12.40 - 12.47 Abstract      
12.50 - 13.05 Cognitive trajectories in IDH mut glioma Isabelle Rydén, Gothenburg/Sweden    
  Brain tumor diagnosis; beyond clinical routine - Chair - Bjarne W. Kristensen      
13.10 - 13.40 Liquid biopsies Susan Short, Leeds/UK    
13.40 - 14.00 Brain Cancer: From Biology to Early Detection Petra Hamerlik, Manchester/UK    
14.00 - 14.15 DNA methylation diagnostics of brain tumors now and in the future Kirsi Rautajoki, Finland    
14.15 - 14.30 PET in diagnosis of brain tumors Ian Law, Copenhagen/DK    
14.30 - 14.37 Abstract      
14.40 - 14.55 Metabolic patterns before glioma diagnosis Sebastian Löding, Umeå/Sweden    
14.55 - 15.15 Coffee/Exhibition      
  Radiotherapy - Chair - Maria Sandström      
15.15 - 15.30 Novel PET tracers in mangement of brain metastasis Pirjo Laakkonen, Helsinki/Finland    
15.30 - 15.45 Swedish proton experience in LGG / PRO GLIO UPDATE Malin Blomstrand, Gothenburg/Sweden    
15.45 - 15.52 Abstract      
15.55 - 16.25 Experience of intraoperative radiotherapy Klaus Henning Kahl, Augsburg/Germany    
  Tumor microenvironment - Chair - Kirsi Rautajoki      
16.30 - 17.00 Tumor-host interdependance Vidhya Madapusi Ravi, Freiburg/Germany    
17.00 - 17.15 Tertiary lymphoid structures; relevance in brain tumors? Anna Dimberg, Uppsala/Sweden    
17.15 - 17.30 Tumor surfaceome - the key to effective immunotherapy? Mattias Belting, Lund/Sweden    
17.30 - 17.45 Influence of the microenvironment on chemosensitivity in glioblastoma Rikke Frydendahl Sick Olsen, Odense/Denmark    
17.45 - 18.00 Coffee/Exhibition      
  Quality of life - Chair - Anja Smits      
18.00 - 18.15 Reproductive health and sexuality Claudia Lampic, Umeå/Sweden    
18.15 - 18.30 Feasibility of shared decision making in neuro-oncology Helle Sørensen Von Essen, Odense/Denmark    
18.30 - 18.45 Functional consequences of SMA and M1 resections Mattias Stålnacke, Umeå/Sweden    
18.45 - 19.00 Support to patients with glioblastoma and their proxies Pernilla Ståhl, Gothenburg/Sweden    
         
April 26
       
  Meningiomas - Chair - Anneli Ozanne      
08.30 - 08.45 Epidemiology and Incidental meningiomas Olivia Näslund, Gothenburg/Sweden    
08.45 - 09.15 Molecular classification of meningiomas Felix Sahm, Heidelberg/Germany    
09.15 - 09.30 Radiotherapy as primary option for meningiomas Bente Sandvei Skeie, Bergen/Norway    
09.30 - 09.45 Copenhagen meningioma score Tiit Mathiesen, Copenhagen/Denmark    
09.45 - 09.52 Abstract      
09.52 - 09.59 Abstract      
10.00 - 10.07 Abstract      
10.07 - 10.14 Abstract      
10.15 - 10.45 Meningiomas, new horizons Thomas Graillon, Marseille/France     
11.00 - 12.00 Poster viewing - Guided      
12.00 - 13.00  Lunch - Symposium (lunchbox) TBA     
  Innovative study designs - Chair - Jiri Bartek      
13.00 - 13.20 Register randomized trials - what can neuro-oncology learn from the BROKEN-SWEDEHEART? Elmir Omerovic, Gothenburg/Sweden    
13.20 - 13.40 Window-of-opprtunity studies Michael Vogelbaum, Tampa/USA    
13.40 - 14.00 Basket and umbrella trials Benedikte Hasselbalch, Copenhagen/Denmark    
  Basic research topic - Chair - Helena Carén      
14.15 - 14.30 Spatial organization of diffuse gliomas Aliisa Tiihonen, Finland    
14.30 - 14.45 GBM organoids, how and why Magnar Bjørås, Trondheim/Norway    
14.45 - 15.00 3D chromatin organization of the glioblastoma genome Silvia Remeseiro, Umeå/Sweden    
15.00 - 15.15 Novel insight into glioblastoma heterogeneity Bjarne W. Kristensen, Copenhagen/Denmark    
15.15 - 15.22 Abstract      
15.22 - 15.29 Abstract      
15.30 - 16.00 Coffee/Exhibition      
  Novel therapies - Chair  - Asgeir Jakola      
16.00 - 16.30 Immunotherapies including CAR-T in neuro-oncology Magnus Essand, Uppsala/Sweden    
16.30 - 17.00 Neurosurgical role in oncological therapy: towards truly multidisciplinary treatment? Michael Vogelbaum, Tampa/USA    
         
19.00 - 22.00 CONGRESS DINNER      
         
April 27        
  Abstract session and New concepts in IDH mutant gliomas - Chair - Asgeir Jakola      
09.00 - 09.10 Best abstract clincal      
09.10 - 09.20 Best abstract clincal      
09.20 - 09.30 Best abstract basic      
09.30 - 09.40 Best abstract basic      
09.40 - 10.10 Vorasidenib in IDH mutated gliomas Roberta Ruda, Turin/Italy    
         
10.10 - 10.30 Coffee/Exhibition      
  Glioma origin and growth - Chair - Magnus Olivecrona      
10.30 - 10.37 Best abstract basic      
10.37 - 10.45 Best abstract basic      
10.45 - 11.00 Are gliomas inheritable? Adam Rosenbaum, Umeå/Sweden    
11.00 - 11.15 Glioma invasion: what can we learn from current models? Sven Nelander, Uppsala/Sweden    
 

Trial updates with focus on the Nordics - Chair - Roger Henriksson

     
11.20 - 11.27 Abstract      
11.28 - 11.35 Abstract      
11.35 - 11.50 Temozolamide and Lomustine in MGMT methylated glioblastoma Annika Malmström, Linköping/Sweden    
11.50 - 12.45  Lunch - Mini symposium  TBA    
  Trial updates with focus on the Nordic countries - Chair - Roger Henriksson      
12.45 - 13.00 Optimized PCNSL treatment with BBB disruption Hanne Kuitunen, Oulo/Finland    
13.00 - 13.15 Scandinavian standard of care in surgical management of LGG Margret Jensdottir, Stockholm/Sweden    
13.15 - 13.30 Skull remodelling to improve TTF Anders Korshøj, Aarhus/Denmark    
13.30 - 13.45 Norwegian Brain Tumor Consortium: improved access to trials Petter Brandal, Oslo/Norway    
13.45 - 14.00  Tumor deliniation, novel fluorescent agents Jane S. Rasmussen, Copenhagen/Denmark    
14.00 - 14.10 ADJOURN Asgeir Jakola, Gothenburg/Sweden    

Skriv ut